A trial investigating the safety and efficacy of a drug combination Ledipasvir/Sofosbuvir for Subjects with hepatitis C who are on dialysis for kidney disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-003489-25

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

 To evaluate the antiviral efficacy of treatment with LDV/SOF for 8,12, or 24 weeks in subjects with chronic hepatitis C virus (HCV) infection who are on dialysis for ESRD, as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR12)  To evaluate the safety and tolerability of each treatment regimen


Critère d'inclusion

  • Chronic hepatitis C virus infection

Liens